NEW YORK (GenomeWeb News) – Shares in Affymetrix plummeted more than 13 percent in afternoon trading today on Nasdaq after an analyst from Barclay's Capital downgraded the firm from "equal weight" to "underweight."

Shares of Affymetrix were trading at $5.58 this afternoon, a decrease of $0.86 from yesterday's closing price of $6.44.

The Barclay's analyst downgraded Affymetrix's stock based on the recent introduction of competing technologies that are rendering Affymetrix's products "obsolete."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.